Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
about
Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug ScreeningTowards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in MacaquerAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in MouseToxocara seroprevalence in patients with idiopathic Parkinson's disease: chance association or coincidence?AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models.α-Synuclein nonhuman primate models of Parkinson's disease.Animal models of α-synucleinopathy for Parkinson disease drug development.Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration.A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.MicroRNAs in Parkinson's disease and emerging therapeutic targets.Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
P2860
Q28547585-0E3F3DC1-C648-4CB8-BCBF-8D879FFB0B21Q28554611-F532B0AF-FF61-4DCB-A682-A90707628CCFQ34465572-FF5827A4-9BB7-4925-BF44-782B9D59A3D1Q35073958-34FF15F0-B187-4F1E-9909-4AE81EAD9254Q35675406-7F71B7EB-B815-4022-9013-990BAB9CEA07Q36665298-A9EF72CE-D30D-4156-BB3B-DE02C1F453A7Q37618665-C589A692-0464-42C6-818B-36ABC45C8EB1Q38607819-81686856-9461-4DFF-8744-4B1379B3E885Q38737932-5D133EF3-BA9F-4648-8F63-2CACCBBDAF83Q38790881-38D72219-17B2-4F61-AE1F-8F3677F28F70Q38805550-DA349EDB-0BC6-47C2-BC95-EBB81562FAFAQ39139260-3367ACC9-1460-40E4-9A85-DE044167B869Q39256792-EDF452C1-EA65-4EF3-8395-1EF756C17538Q40106906-D0C5B9D0-DEA2-45F2-8E78-6C58571D53CBQ40108542-A9B2156D-7059-43A6-B755-02363C92EBA0Q41135381-C8969036-0614-49AC-A1AF-6DB7917963EFQ41740088-72983E89-CA2C-42D4-AE34-31C2B290848EQ42243394-058753AC-5FAF-4988-B782-1BC81C4C691FQ43247253-699ED1F7-7D3C-4295-A9AD-9E9D265DF0ADQ47870847-3A7C1DF8-C444-49C9-9802-ADC843513A1AQ50199812-C22DCA32-AC9C-41E1-B65F-1E0A8C997E91Q53684476-D0FD0111-BEA8-4F1F-B8ED-7DE3C1AB424F
P2860
Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Progressive neurodegeneration ...... sing doses of alpha-synuclein.
@ast
Progressive neurodegeneration ...... sing doses of alpha-synuclein.
@en
type
label
Progressive neurodegeneration ...... sing doses of alpha-synuclein.
@ast
Progressive neurodegeneration ...... sing doses of alpha-synuclein.
@en
prefLabel
Progressive neurodegeneration ...... sing doses of alpha-synuclein.
@ast
Progressive neurodegeneration ...... sing doses of alpha-synuclein.
@en
P2093
P2860
P1433
P1476
Progressive neurodegeneration ...... sing doses of alpha-synuclein.
@en
P2093
James B Koprich
M Gabriela Reyes
Maria Espinosa
Philippe Huot
P2860
P304
P356
10.1371/JOURNAL.PONE.0017698
P407
P577
2011-03-07T00:00:00Z